The deposition of a former C.R. Bard president responsible for the creation and promotion of C.R. Bard’s Avaulta mesh product was played for the jury on August 6 in a bellwether trial being heard in the U.S. District Court for the Southern District of West Virginia. According to a Drug Watch report on the C.R. Bard multidistrict litigation (MDL) bellwether trial, the filmed deposition lasted for seven hours.
The deposition’s contents are quite revealing, in that they present a lack of awareness, effort, and care on the part of the former president in addressing concerns related to the Avaulta’s design.
The bellwether trial involves the plaintiff, Donna Cisson, who received an implant of C.R. Bard’s Avaulta transvaginal mesh. In filing her transvaginal mesh lawsuit, Cisson claims that the Avaulta mesh is a defective product and is the source of her serious injuries.
Due to mounting reports from women who experienced injuries following surgery to implant transvaginal mesh, the U.S. Food and Drug Administration (FDA) began a review of data on implantation of transvaginal mesh products to treat pelvic organ prolapse (POP). In their review, the FDA discovered that patients most often experienced transvaginal mesh erosion or contraction. In addition, women who alleged to have been injured by transvaginal mesh quite often claimed that the mesh caused severe pelvic pain, bleeding, infection, organ damage, and painful intercourse.
Carey Danis & Lowe attorneys continue to take questions from women who claim to have been harmed by a transvaginal mesh product. Contact a transvaginal mesh lawyer at Carey Danis & Lowe for a free legal evaluation. Our attorneys and health care experts are here to listen to your story, and to provide you with expert legal and medical advice.
Call 800.721.2519 or submit a personal injury claim form.
